Moreover, there is some evidence that polymorphisms of detoxifying glutathione-S-transferases (GSTs) may have an influence on the outcome of CPA treatment; homozygous variant GSTA1*B/*B genotype was related to reduced mortality during the first 5 years after diagnosis of breast cancer [20] and the low activity associated GSTP1 Val105Val genotype has been reported to confer to better survival [21]. Here, HPGDS is linked to breast cancer.